216 related articles for article (PubMed ID: 28052520)
21. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity.
Liu J; Song T; Zhou W; Xing L; Wang S; Ho M; Peng Z; Tai YT; Hideshima T; Anderson KC; Cang Y
Leukemia; 2019 Jan; 33(1):171-180. PubMed ID: 30026574
[TBL] [Abstract][Full Text] [Related]
22. RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation.
Zhou N; Gutierrez-Uzquiza A; Zheng XY; Chang R; Vogl DT; Garfall AL; Bernabei L; Saraf A; Florens L; Washburn MP; Illendula A; Bushweller JH; Busino L
Leukemia; 2019 Aug; 33(8):2006-2021. PubMed ID: 30760870
[TBL] [Abstract][Full Text] [Related]
23. Immunomodulatory drugs in the treatment of multiple myeloma.
Abe Y; Ishida T
Jpn J Clin Oncol; 2019 Aug; 49(8):695-702. PubMed ID: 31187860
[TBL] [Abstract][Full Text] [Related]
24. Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma.
Shi CX; Kortüm KM; Zhu YX; Jedlowski P; Bruins L; Braggio E; Stewart AK
Haematologica; 2015 Aug; 100(8):e315-7. PubMed ID: 25975838
[No Abstract] [Full Text] [Related]
25. Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase.
Petzold G; Fischer ES; Thomä NH
Nature; 2016 Apr; 532(7597):127-30. PubMed ID: 26909574
[TBL] [Abstract][Full Text] [Related]
26. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
Anderson KC
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
[TBL] [Abstract][Full Text] [Related]
27. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Weber DM; Chen C; Niesvizky R; Wang M; Belch A; Stadtmauer EA; Siegel D; Borrello I; Rajkumar SV; Chanan-Khan AA; Lonial S; Yu Z; Patin J; Olesnyckyj M; Zeldis JB; Knight RD;
N Engl J Med; 2007 Nov; 357(21):2133-42. PubMed ID: 18032763
[TBL] [Abstract][Full Text] [Related]
28. [Thalidomide, cereblon and multiple myeloma].
Ogura T
Nihon Rinsho; 2015 Jan; 73(1):149-55. PubMed ID: 25626321
[TBL] [Abstract][Full Text] [Related]
29. The clinical significance of cereblon expression in multiple myeloma.
Schuster SR; Kortuem KM; Zhu YX; Braggio E; Shi CX; Bruins LA; Schmidt JE; Ahmann G; Kumar S; Rajkumar SV; Mikhael J; Laplant B; Champion MD; Laumann K; Barlogie B; Fonseca R; Bergsagel PL; Lacy M; Stewart AK
Leuk Res; 2014 Jan; 38(1):23-8. PubMed ID: 24129344
[TBL] [Abstract][Full Text] [Related]
30. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
Morgan G
Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
[TBL] [Abstract][Full Text] [Related]
31. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
Richardson P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
[TBL] [Abstract][Full Text] [Related]
32. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.
Lopez-Girona A; Heintel D; Zhang LH; Mendy D; Gaidarova S; Brady H; Bartlett JB; Schafer PH; Schreder M; Bolomsky A; Hilgarth B; Zojer N; Gisslinger H; Ludwig H; Daniel T; Jäger U; Chopra R
Br J Haematol; 2011 Aug; 154(3):325-36. PubMed ID: 21707574
[TBL] [Abstract][Full Text] [Related]
33. Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents.
Chen CI; Masih-Khan E; Jiang H; Rabea A; Cserti-Gazdewich C; Jimenez-Zepeda VH; Chu CM; Kukreti V; Trudel S; Tiedemann R; Tsang R; Reece DE
Br J Haematol; 2013 Aug; 162(4):483-8. PubMed ID: 23772701
[TBL] [Abstract][Full Text] [Related]
34. Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1.
Wu W; Nelson GM; Koch R; Donovan KA; Nowak RP; Heavican-Foral TB; Nirmal AJ; Liu H; Yang L; Duffy J; Powers F; Stevenson KE; Jones MK; Ng SY; Wu G; Jain S; Xu R; Amaka S; Trevisani C; Donaldson NL; Hagner PR; de Leval L; Gaulard P; Iqbal J; Thakurta A; Fischer ES; Adelman K; Weinstock DM
Blood; 2022 Mar; 139(13):2024-2037. PubMed ID: 34936696
[TBL] [Abstract][Full Text] [Related]
35. Development of Label-Free Impedimetric Immunosensors for IKZF1 and IKZF3 Femtomolar Detection for Monitoring Multiple Myeloma Patients Treated with Lenalidomide.
Abdulkarim H; Zourob M; Siaj M
Sci Rep; 2020 Jun; 10(1):10424. PubMed ID: 32591583
[TBL] [Abstract][Full Text] [Related]
36. A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma.
Kim GW; Yoo J; Won HR; Yeon SK; Lee SW; Lee DH; Jeon YH; Kwon SH
Leuk Res; 2020 Aug; 95():106398. PubMed ID: 32512378
[TBL] [Abstract][Full Text] [Related]
37. Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels.
Greenberg AJ; Walters DK; Kumar SK; Rajkumar SV; Jelinek DF
Eur J Haematol; 2013 Dec; 91(6):504-13. PubMed ID: 23992230
[TBL] [Abstract][Full Text] [Related]
38. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.
Krönke J; Udeshi ND; Narla A; Grauman P; Hurst SN; McConkey M; Svinkina T; Heckl D; Comer E; Li X; Ciarlo C; Hartman E; Munshi N; Schenone M; Schreiber SL; Carr SA; Ebert BL
Science; 2014 Jan; 343(6168):301-5. PubMed ID: 24292625
[TBL] [Abstract][Full Text] [Related]
39. The novel mechanism of lenalidomide activity.
Fink EC; Ebert BL
Blood; 2015 Nov; 126(21):2366-9. PubMed ID: 26438514
[TBL] [Abstract][Full Text] [Related]
40. IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos.
Fedele PL; Willis SN; Liao Y; Low MS; Rautela J; Segal DH; Gong JN; Huntington ND; Shi W; Huang DCS; Grigoriadis G; Tellier J; Nutt SL
Blood; 2018 Nov; 132(20):2166-2178. PubMed ID: 30228232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
